Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study
| Autor: | Huda Imam Gasmelseed, Abubaker Suliman, Shamma Alawi, Farrukh Sheikh, Zahir Osman Eltahir Babiker, Abderrahim Oulhaj, Yaman Hukan, Harald Sourij, Junu A. George, Juergen Prattes, Shaima Khan, Ahmed R. Alsuwaidi, Fayez Alshamsi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine ARDS urokinase plasminogen activator Infectious and parasitic diseases RC109-216 law.invention Patient Admission 0302 clinical medicine law Clinical endpoint Prospective Studies 030212 general & internal medicine Prospective cohort study COVID-19 coronavirus disease 2019 LDH lactate dehydrogenase Acute respiratory distress syndrome Incidence (epidemiology) Hazard ratio ELISA enzyme-linked immunosorbent assay General Medicine Middle Aged All-cause mortality ICU intensive care unit Intensive care unit Intensive Care Units Infectious Diseases CRP C-reactive protein Female medicine.drug RT-PCR reverse-transcriptase polymerase chain reaction Adult Microbiology (medical) medicine.medical_specialty 030106 microbiology SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 Article Receptors Urokinase Plasminogen Activator 03 medical and health sciences suPAR soluble urokinase Plasminogen Activator Receptor UAE United Arab Emirates Internal medicine medicine Humans Urokinase plasminogen activator ARDS acute respiratory distress syndrome Aged Urokinase SARS-CoV-2 business.industry COVID-19 medicine.disease CI confidence interval Intensive care admission SuPAR SD standard deviation business |
| Zdroj: | International Journal of Infectious Diseases, Vol 107, Iss, Pp 188-194 (2021) International Journal of Infectious Diseases |
| ISSN: | 1201-9712 |
| Popis: | OBJECTIVE: To examine the association between plasma levels of the soluble urokinase plasminogen activator receptor (suPAR) and the incidence of severe complications of COVID-19. METHODS: 403 RT-PCR-confirmed COVID-19 patients were recruited and prospectively followed-up at a major hospital in the United Arab Emirates. The primary endpoint was time from admission until the development of a composite outcome, including acute respiratory distress syndrome (ARDS), intensive care unit (ICU) admission, or death from any cause. Patients discharged alive were considered as competing events to the primary outcome. Competing risk regression was used to quantify the association between suPAR and the incidence of the primary outcome. RESULTS: 6.2% of patients experienced ARDS or ICU admission, but none died. Taking into account competing risk, the incidence of the primary outcome was 11.5% (95% confidence interval [CI], 6.7-16.3) in patients with suPAR levels >3.91 ng/mL compared to 2.9% (95% CI, 0.4-5.5) in those with suPAR ≤3.91 ng/mL. Also, an increase by 1 ng/mL in baseline suPAR resulted in a 58% rise in the hazard of developing the primary outcome (hazard ratio 1.6, 95% CI, 1.2-2.1, p = 0.003). CONCLUSION: suPAR has an excellent prognostic utility in predicting severe complications in hospitalised COVID-19 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|